Controlling Oral Malodor by ClōSYS Oral Rinse

NCT ID: NCT03160573

Last Updated: 2020-12-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 99 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-11-30
• Study Completion Date: 2017-02-28

Brief Summary

The purpose of this Study is to assess the efficacy of two ClōSYS Oral Rinse products in human subjects in controlling oral malodor in partial fulfillment of the requirements for recognition by the American Dental Association's (ADA) requirement for obtaining ADA Seal for malodor.

Detailed Description

Study Design:

The products used in this study are: ClōSYS Alcohol-Free Oral Rinse (referred here as ClōSYS Unflavored Oral Rinse) and ClōSYS justRIGHT MILD MINT Oral Rinse (referred here as ClōSYS Flavored Oral Rinse). This is an in-vivo, eight-week, a single-center, randomized, double-blind (subject/investigator), 2-waycross-overdesign clinical study. There will be two independent groups. Each subject of each group will be crossed over to the other group within a same group after the washout period. Each group will have their own control group. In the first phase, 25 subjects (50%) of each group will randomly be assigned to the active group; the other 25 subjects will be assigned to the control group. In the second phase, the participants will be crossed over of group assignment. The Study will enroll 100 subjects, aged 21 to 65 years, with a slight to strong intrinsic oral malodor, as determined by a panel of trained odor judges calibrated and standardized using a range of standard odorants sufficient to reflect the different patterns of nose receptors.

Study Plan:

Subjects will receive verbal and written oral hygiene instructions, and either one bottle (16 oz. each) of ClōSYS Unflavored Oral Rinse, ClōSYS Flavored Oral Rinse- or Placebo Oral Rinse each week. Subjects will also receive measuring cups for dispensing the rinse and a diary log for recording usage (the Oral Hygiene Kit) for use during the treatment. After a 2-week wash out period, each subject will receive another bottle of oral rinse according to their group assignment. The rinse bottles will be weighed prior to dispensing the product. A product log will be maintained and the weights of the bottles will be documented at each visit.

Subjects will be instructed to rinse twice a day, each in the morning and in the evening, with 15 mL mouth rinse for 30 seconds. They will note in their patient's log the date and time of rinsing.

Subjects will be instructed to continue with their normal oral hygiene practices, including tooth brushing and flossing but omitting any use of oral rinses or mouthwashes except for the Study materials. The subjects also will be instructed not to use other non-study related products such as breath mints, lozenge, gums, etc. as well as refraining from elective dental procedures during the study period.

Conditions

Oral Malodor

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Test-Unflavored Rinse then Placebo Unflavored Rinse

Participants will receive CloSYS unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks,. After a washout period of 2 weeks, they will then receive Placebo unflavored rinse containing containing NO 0.1% stabilized chlorine dioxide for 3 weeks.

Group Type: ACTIVE_COMPARATOR

ClōSYS® Unflavored Rinse

Intervention Type: DRUG

Test-Flavored Rinse then Placebo Flavored Rinse

Participants will receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks. After a washout period of 2 weeks, they will then receive Placebo flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks.

Group Type: ACTIVE_COMPARATOR

ClōSYS® Flavored Rinse

Intervention Type: DRUG

Flavored Oral Rinse-Placebo then Test-Flavored Rinse

Participants will receive CloSYS mint flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo-Flavored Oral Rinse

Intervention Type: OTHER

Flavor-matched placebo rinse

Unflavored Oral Rinse-Placebo then Test-Unflavored Rinse

Participants will receive CloSYS unflavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo-Unflavored Oral Rinse

Intervention Type: OTHER

Unflavored-matched placebo rinse

Interventions

ClōSYS® Unflavored Rinse

Intervention Type: DRUG

ClōSYS® Flavored Rinse

Intervention Type: DRUG

Placebo-Flavored Oral Rinse

Flavor-matched placebo rinse

Intervention Type: OTHER

Placebo-Unflavored Oral Rinse

Unflavored-matched placebo rinse

Intervention Type: OTHER

Other Intervention Names

Mouth rinse; Mouth rinse

Eligibility Criteria

Inclusion Criteria

1. Subject has read, signed, and received a copy of the Informed Consent prior to Study initiation.

2. Subject is able to follow verbal and/or written instructions, perform oral hygiene procedures and return to the test facility for specified Study examinations.

3. Subject is between the ages of 21 and 65 years of age, male or female.

4. Subject has normal oral interior cheek wall tissues.

5. Subject is in good general health as determined by medical history and clinical judgment that no severe or debilitating disease exists that would impede participation in the Study.

6. Subject must have an average organoleptic intensity rating of at least 2.6 but maximum 4.5 on an intensity scale of 0-5.

Exclusion Criteria

1. Pregnant or nursing per subject report.

2. Diagnosis of Xerostomia, including medication induced Xerostomia.

3. Any oral or extraoral piercing that interferes with the ability to perform study procedures and/or clinical assessments in the mouth.

4. Fixed or removable oral appliance, such as orthodontic brackets or retainer, partial or complete dentures.

5. Have advanced periodontal disease or excessive gingival recession, per Investigator/Examiner discretion.

6. A known allergy or sensitivity to products planned for use in this study.

7. Unwillingness to abstain from all other oral hygiene products other than those prescribed for the duration of the study.

8. Heavy deposits of calculus, either supragingival and/or subgingival, per Investigator/Examiner discretion.

9. Have a history of severe transmittable infectious disease (hepatitis, HIV, tuberculosis).

10. Have a medical or dental condition that would be unduly affected by participation in this study, per Investigator discretion.

11. Any other condition that Principal Investigator would consider interfering with the study.

12. Smokers.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Health Resources Group, Inc.

OTHER

Sponsor Role: collaborator

Rowpar Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sushma Nachnani, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University Health Resources Group, Inc.

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

UHRG-RPR-Malodor-ADA-2016

Identifier Type: -

Identifier Source: org_study_id